BIOVEN 3 LTD has a total of 33 patent applications. It decreased the IP activity by 66.0%. Its first patent ever was published in 2012. It filed its patents most often in China, Republic of Korea and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are PROBE INTERNAT, PASTAN IRA H and CSL Behring Lengnau AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 6 | |
#2 | Republic of Korea | 4 | |
#3 | United States | 4 | |
#4 | WIPO (World Intellectual Property Organization) | 4 | |
#5 | Canada | 3 | |
#6 | Mexico | 3 | |
#7 | Brazil | 2 | |
#8 | EPO (European Patent Office) | 2 | |
#9 | Japan | 2 | |
#10 | Hong Kong | 1 | |
#11 | Israel | 1 | |
#12 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Climate change mitigation in goods production |
# | Name | Total Patents |
---|---|---|
#1 | Charlton Keith Alan | 18 |
#2 | D'Hondt Erik | 12 |
#3 | D Hondt Erik | 11 |
#4 | Verhamme Daniel T | 7 |
#5 | Molina Vila Miguel Angel | 6 |
#6 | Dhondt Erik | 5 |
#7 | Keith Alan Charlton | 4 |
#8 | Erik D'Hondt | 2 |
#9 | Erik D´Hondt | 2 |
#10 | D'Ondt Erik | 1 |
Publication | Filing date | Title |
---|---|---|
US2016333087A1 | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors | |
CA2904506A1 | Self-assembling synthetic proteins | |
CN108864261A | Recombinant protein and its therapeutical uses |